Precision Medicine Group Appoints John Hubbard, PhD, as Board of Directors Chair
BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”